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Abstract Correct diagnosis of inherited bone marrow failure syndromes is a challenge
because of the significant overlap in clinical presentation of these disorders. Establishing
right genetic diagnosis is crucial for patients’ optimal clinical management and family
counseling. A nondysmorphic infant reported here developed severe transfusion-depen-
dent anemia and met clinical criteria for diagnosis of Diamond–Blackfan anemia (DBA).
However, whole-exome sequencing demonstrated that the child was a compound hetero-
zygote for a paternally inherited pathogenic truncating variant (SPTA1c.4975 C>T) and a novel
maternally inherited missense variant of uncertain significance (SPTA1c.5029 G>A) within the
spectrin gene, consistent with hereditary hemolytic anemia due to disruption of red blood
cell (RBC) cytoskeleton. Ektacytometry demonstrated abnormal membrane flexibility of the
child’s RBCs. Scanning electron microscopy revealed morphological aberrations of the pa-
tient’s RBCs. Both parents were found to have mild hereditary elliptocytosis. Importantly,
patients with severe RBC membrane defects may be successfully managed with splenec-
tomy to minimize peripheral destruction of misshapen RBCs, whereas patients with DBA re-
quire lifelong transfusions, steroid therapy, or hematopoietic stem cell transplantation. As
suggested by the WES findings, splenectomy rendered our patient transfusion-indepen-
dent, improving the family’s quality of life and preventing transfusion-related iron overload.
This case illustrates the utility of whole-exome sequencing in clinical care of children with
genetic disorders of unclear presentation.
INTRODUCTION
Diagnosis of inherited bone marrow failure syndromes is remarkably difficult because of
the striking clinical heterogeneity of these rare diseases. Many patients lack a clear physical
or laboratory profile to guide expert clinicians toward a specific single-gene test (Nalepa and
Clapp 2018). Therapies required in the setting of acute illness may cloud the ability to pursue
diagnostic tests at a later time—for example, blood transfusions may suppress abnormal
hematopoiesis and alleviate hemolysis in congenital hemolytic anemia. Nevertheless, it is
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ultimately essential to establish a diagnosis to recommend management and evidence-
based counseling for families affected with these uncommon genetic disorders. Therefore,
whole-exome sequencing (WES) is increasingly utilized for unbiased clinical diagnostics in
individuals whose symptoms are suggestive of a hereditary disease but not sufficiently spe-
cific for targeted gene sequencing (Biesecker and Green 2014).
When WES reveals variants of unknown significance (VUS), functional evaluation of the
resulting protein changes corroborates the diagnostic findings andmay offer clinically useful
insights into disease pathogenesis. Ultimately, this approach may unravel unexpected ther-
apeutic options for the affected family. Here, we discuss a child affectedwith amisdiagnosed
genetic disorder, in which WES supported by experimental validation of novel genomic var-
iants established the correct diagnosis and inspired major changes to the proband’s and
family’s clinical management, eliminating the need for chronic red blood cell (RBC)
transfusions.
RESULTS
A nondysmorphic Caucasian infant female was referred to us for management of suspected
DBA based on transfusion-dependent anemia since the age of 2 mo when she presented
with a severe anemia (hemoglobin 3.2 g/dl) and absolute reticulocyte count of 98 K/mm3,
which was inappropriately low for the degree of anemia (Buttarello 2016). DBA is a clinically
heterogeneous disorder, and consensus diagnostic criteria for “classical” DBA include age
of <1 yr at the time of anemia onset, low reticulocyte count, lack of other significant cytope-
nias, and decreased erythrocytic precursors without other major abnormalities in the bone
marrow. A positive family history and the presence of mutations within known DBA genes
are considered major supporting diagnostic criteria in this complex syndrome; congenital
anomalies, elevated adenosine deaminase (ADA), and fetal hemoglobin (Hgb F) represent
further minor supporting criteria for DBA (Vlachos et al. 2008). The patient’s family history
was reported as normal. Her ADA, pyruvate kinase (PK) activity, and fetal hemoglobin
(HgbF) were not tested before the first transfusion. Her bone marrow evaluation was non-
diagnostic as specimen dilution prevented quantification of erythroid precursors. There
was no jaundice concerning for hemolytic anemia. Given the unclear clinical picture, we con-
sidered atypical DBA or another inherited disorder of hematopoiesis. As steroids improve
erythropoiesis in DBA and rendermost patients transfusion-independent (Ball 2011), we pur-
sued a trial of prednisone (2 mg/kg PO daily) and observed an initial hemoglobin increase to
9.4 g/dl followed by a drop to 5.7 g/dl within a month; therefore, we classified the patient as
steroid nonresponsive and discontinued her prednisone. Her DBA-focused sequencing pan-
el and copy-number variation microarray were normal.
The patient required monthly RBC transfusions and developed one hemolytic episode
associated with viral illness, resulting in pallor, mild hyperbilirubinemia, and, unexpectedly
for presumptive diagnosis of DBA, mild reticulocytosis. We decided to pursue whole-exome
sequencing (WES) of the child and her parents to determine the potential underlying inher-
ited cause of her clinical course and allow genetic counseling.
WES of the family revealed that the patient is a compound heterozygote for two eryth-
rocytic α-spectrin (SPTA1) variants, consistent with hereditary pyropoikilocytosis (Table 1).
The first truncating SPTA1 variant inherited from the father (c.4975C>T; p.R1659X) had
been reported in hereditary pyropoikilocytosis (Tolpinrud et al. 2008). The second maternal-
ly inherited SPTA1 variant resulted in a novel missense substitution (c.5029G>A; p.G1677R).
This variant affects a conserved spectrin domain outside of the spectrin self-association site
and is predicted to be deleterious by PROVEAN and PolyPhen-2 algorithms. Neither SPTA1
genetic variant was observed in approximately 6000 individuals of European and African
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American ancestry in the NHLBI Exome Sequencing Project, indicating these are not com-
mon benign variants in these populations. In retrospect, both parents had a history of
mild unexplained anemia with occasional peripheral elliptocytes and the father had chronic
hyperbilirubinemia suggestive of hemolysis, consistent with a diagnosis of mild hereditary
elliptocytosis (Gallagher 2005).
Review of the patient’s pretransfusion smear (Fig. 1A) combined with scanning electron
microscopy (Fig. 1B) revealed microspherocytes, anisopoikilocytosis, and budding RBCs,
consistent with congenital hemolytic anemia due to α-spectrin deficiency resulting in dys-
functional RBC membrane cytoskeleton. The patient’s RBC membrane protein electropho-
resis showed the presence of β-spectrin, whereas α-spectrin was nearly undetectable (Fig.
1C). Ektacytometry, performed 2 mo after transfusion, detected abnormal RBC flexibility
(Fig. 1D). Elliptocytes and occasional spherocytes were found on both parents’ peripheral
blood smears, consistent with the diagnosis of hereditary elliptocytosis. Given these genetic
findings and ongoing transfusion needs, the child underwent partial laparoscopic splenec-
tomy removing the distal 85% of the spleen, which resulted in transfusion independence
for 12 mo (her transfusion threshold was 7 g/dl). However, the patient’s transfusion depen-
dence recurred with hemoglobin nadir of 5.9 g/dl, correlating with regrowth of her spleen
tissue reported on abdominal ultrasound. The patient next underwent full laparoscopic sple-
nectomy. She remains transfusion-independent with normal hemoglobin more than 6 mo
postsplenectomy.
DISCUSSION
Our patient initially received the clinical diagnosis of suspected DBA based on the severe
transfusion-dependent anemia with reticulocytopenia starting in infancy. DBA represents a
group of genetically distinct ribosomopathies that manifest hematologically as severely im-
paired erythropoiesis, although it is not clear how genetic impairment of the ribosome selec-
tively arrests RBC production and produces a wide variety of systemic manifestations that
vary between patients (Ruggero and Shimamura 2014; Vlachos et al. 2014). Lack of dysmor-
phic features did not exclude this possibility as roughly half of DBA patients are free of gross
malformations (Da Costa et al. 2017). Our patient’s ADA activity and hemoglobin F (HgbF)
were not tested before her first transfusion and referral to our center. Moreover, we initially
did not consider an underlying hemolytic anemia as the cause of her transfusion dependency
as she was not jaundiced and did not have gross anipoikilocytosis on her posttransfusion pe-
ripheral blood smears, likely because her own erythropoiesis was significantly suppressed by
monthly transfusions. However, our retrospective review of her previously inaccessible pre-
transfusion blood smear revealed anisopoikilocytosis that should have raised the concern of
an underlying RBC membrane disorder. These diagnostic challenges highlight the impor-
tance of early consultation and provision of original blood and marrow specimens to pediat-
ric hematologists with expertise in inherited bone marrow failure syndromes.
Consistent with a structurally and functionally abnormal RBC membrane cytoskeleton,
we observed microspherocytes and bizarrely shaped RBCs on patient’s posttransfusion
Table 1. Genomic findings
Gene Genomic location HGVS cDNA HGVS protein Zygosity Parent of origin Variant interpretation
SPTA1 Chromosome 1, NC_000001.11 c.4975 C>T p.R1659X Heterozygous Father Pathogenic
SPTA1 Chromosome 1, NC_000001.11 c.5029G>A p.G1677R Heterozygous Mother Variant of unknown significance
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RBC scanning electron microscopy but not in the blood of healthy controls processed
and imaged in the samemanner (Fig. 1B). Notably, the simplified approach to RBC scanning
electron microscopy we have developed for this work produced high-quality RBC images,
suggesting the potential utility of this technically easy strategy to examine RBC struc-
ture in more detail compared to conventional microscopy. Ektacytometry confirmed
abnormal deformability of the patient’s RBCs resulting from the biochemically validated
deficiency of RBC membrane-associated α-spectrin in this child (Fig. 1C,D); in fact, it likely
underestimated the severity of RBC membrane defect because these experiments were




Figure 1. Red blood cell (RBC) membrane protein deficiency identified via whole-exome sequencing.
(A) Compound heterozygous SPTA1 mutations identified via whole-exome sequencing in a child with trans-
fusion-dependent anemia. Note anisopokilocytosis, microcytes, and elliptocytes on the peripheral blood
smear. Elliptocytes in parents’ peripheral smears are consistent with diagnosis of hereditary elliptocytosis.
(Insert) Location of the new SPTA1 variant within the spectrin fold. Arrow indicates the affected proband.
Healthy brother (white square) was not genetically tested. Mother and father are represented by gray circle
and square, respectively. Severity of phenotype in the family members is reflected by grayscale gradient.
(B) Microspherocytes (yellow arrows), elliptocyte (green arrow), and RBC with membrane extrusions (blue ar-
rows) visualized via scanning electron microscopy in peripheral blood of the patient compared to healthy con-
trol. (C ) Decreased α-spectrin protein in the index patient’s RBCs. (D) Decreased RBC deformability in the
index patient.
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SPTA1p.R1659X/p.G1677R RBCs. Although this study did not examine the relative contribution
of the paternal (p.R1659X) and maternal (p.G1677R) mutation, we hypothesize the paternal
mutation is more severe as it truncates the protein and the father had a known mild border-
line hemolysis.
Different pathophysiology of DBA and RBC membrane disorders provides distinct ther-
apeutic opportunities. In DBA, anemia is caused by impaired RBC production. Steroids res-
cue erythropoiesis in >50% of DBA patients; others require RBC transfusions for their
lifetimes or hematopoietic stem cell transplantation (Vlachos and Muir 2010). Long-term
care of these complex patients requires aggressive management of toxic iron overload re-
sulting from chronic transfusions, side effects of chronic steroid use, as well as cancer surveil-
lance. Contrastingly, in hereditary RBC membranopathies, anemia is caused by elimination
of misshapen RBCs by spleen macrophages beyond the bone marrow’s ability to compen-
sate for hemolysis. Therefore, splenectomy provides a viable surgical option to manage
severe RBC membrane disorders. However, the potential benefits of decreased transfusion
dependency must be balanced with the long-term risk of overwhelming postsplenectomy
infections (OPSIs) (Jugenburg et al. 1999; Edgren et al. 2014) requiring immunizations
against encapsulated bacteria as well as prophylactic penicillin (Davies et al. 2011).
Subtotal splenectomy may alleviate transfusion dependency in severe hereditary spherocy-
tosis (Bader-Meunier et al. 2001; Buesing et al. 2011) and neonatal pyropoikilocytosis
(Medejel et al. 2008) without increasing the risk of OPSIs and thrombosis. Some (Medejel
et al. 2008) but not all (Rice et al. 2003; Buesing et al. 2011) children with hemolytic anemia
post–partial splenectomy require full splenectomy at a later time. Therefore, the risks and
benefits of splenectomy in children with RBCmembrane disorders should be carefully exam-
ined on a personalized basis.
In our patient, we decided to initially proceed with partial splenectomy because of the
patient’s young age. Although this approach provided a temporary decrease in transfusion
needs, our patient ultimately required a complete splenectomy >12 mo later as her trans-
fusion-dependent anemia reoccurred, presumably because of increased RBC destruction
in the expanding remainder splenic tissue. Total splenectomy eliminated our patient’s
transfusion dependence, halting her transfusion-related iron overload and exposure to
blood products, minimizing her need for clinic visits. The diagnosis not only allowed ge-
netic counseling for the family but also provided information relevant to the parents’ health
maintenance, including their risk of chronic hemolysis and cholelithiasis due to chronic
subclinical hemolysis. Interestingly, the child’s father had been undergoing evaluation
for suspected Gilbert’s syndrome at another facility because of mild asymptomatic hyper-
bilirubinemia, which we now believe is due to his chronic hemolysis secondary to his
SPTA1R1659X truncation.
WES is not free of limitations. First, this diagnostic technique will not identify pathogenic
mutations located outside of the exome and may not capture large DNA deletions or dupli-
cations (Nalepa and Clapp 2018). Second, identification of VUS may cause unique challeng-
es as detailed functional analysis of VUSs, as reported in this study, is not always possible.
However, this case illustrates the clinical utility of WES in children with rare congenital disor-




Patients’ and parents’ diagnostic whole-exome sequencing of nuclear and mitochondrial
DNA was done at GeneDx. Using genomic DNA from the submitted specimen, the Agilent
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Clinical Research Exome kit was used to target the exonic regions and flanking splice junc-
tions of the genome. These targeted regions were sequenced simultaneously by massively
parallel (NextGen) sequencing on an Illumina HiSeq 2000 sequencing system with 100-bp
paired-end reads. Bidirectional sequence was assembled, aligned to reference gene se-
quences based on human genome build GRCh37/UCSC hg19, and analyzed for sequence
variants using a custom-developed analysis tool (Xome Analyzer). Capillary sequencing or
another appropriate method was used to confirm all potentially pathogenic variants identi-
fied in this individual and relative samples. Sequence alterations were reported according to
the Human Genome Variation Society (HGVS) nomenclature guidelines. Mean depth of cov-
erage (mean number of sequence reads obtained across the whole exome; specifically, the
coding exons and splice junctions of protein-coding RefSeq genes that are captured by the
Agilent Clinical Research Exome kit) was 111×. Additionally, the entire mitochondrial ge-
nome from each sample was amplified and sequenced using a solid-state sequencing by
synthesis process. DNA sequence was assembled and analyzed in comparison with the re-
vised Cambridge Reference Sequence (rCRS) and the reported variants and polymorphisms
listed in the MITOMAP database (http://www.mitomap.org). The initial DBA next-gen panel
(RPS19, RPL5, RPS10, RPL11, RPL35A, RPS26, RPS24, RPS17, RPS7, RPL19, and RPL26) was
done at Ambry Genetics. See Table 2 for the WES metrics.
RBC Evaluation
For scanning electron microscopy, blood samples in fixative (2% paraformaldehyde/2% glu-
taraldehyde in phosphate buffer) were air-dried on silicon wafers overnight. Then gold-pal-
ladium sputter coating specimens were viewed and imaged with a JEOL, LV 6390 (Peabody)
Scanning Electron Microscope. Peripheral blood smear images were acquired on a Zeiss
Axio Lab.A1 microscope with an Axiocam 105 color camera and processed with ZEN
(Carl-Zeiss) and Imaris (Bitplane) software. Osmotic gradient ektacytometry was performed
and interpreted at the RBC Laboratory, Children’s Oakland Research Institute, UCSF
Benioff’s Children’s Hospital, Oakland, CA. Specimen was shipped overnight in room tem-
perature and accompanied by healthy travel control to ensure results are not affected by
shipping.
ADDITIONAL INFORMATION
Data Deposition and Access
The variants were submitted to ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/) and can be
found under accession numbers SCV000804855.1 and SCV000804576. Patient consent
was not obtained for deposition of raw sequencing data.
Ethics Statement
Informed consent was obtained from the proband’s parents. Clinical specimen biobanking
was approved by the IU School of Medicine Institutional Review Board under the Indiana
Pediatric Biobank protocol (IRB #1501467439).
Table 2. Whole-exome sequencing metrics
Mean depth of coverage 111×
Percentage of exome with at least 10× coverage 96.1%
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